TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2892256

Group type: EXPERIMENTAL
Intervention: Nizatidine 150 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Nizatidine 300 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Cimetidine 800 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Famotidine 40 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 31949115

Group type: EXPERIMENTAL
Intervention: Gefapixant (doses ≥30 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gefapixant (doses ≥150 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30538021

Group type: EXPERIMENTAL
Intervention: Dementia RElAted Manual for Sleep; STrAtegies for RelaTives (DREAMS START) - a six-session manual-based intervention for carers, delivered by trained psychology graduates.
Number of subjects: 62

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 62
Study: 28379925

Group type: EXPERIMENTAL
Intervention: Medically graded bee honey at 5 g/day
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Medically graded bee honey at 10 g/day
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Medically graded bee honey at 15 g/day
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (0 g/day honey)
Number of subjects: 40
Study: 25741642

Group type: EXPERIMENTAL
Intervention: NIH ARDS Network PBW equation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Actuarial table PBW equation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Stewart PBW equation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: General findings
Number of subjects: 0
Study: 23076993

Group type: EXPERIMENTAL
Intervention: Vestibular-specific neuromuscular training for six weeks
Number of subjects: 23

Group type: COMPARATOR
Intervention: Regular activities at school
Number of subjects: 23
Study: 22229233

Group type: EXPERIMENTAL
Intervention: intradermal non-absorbable suture
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: intradermal non-absorbable double layer suture
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: staples
Number of subjects: 140

Group type: COMPARATOR
Intervention: tissue adhesive
Number of subjects: 140
Study: 19178577

Group type: EXPERIMENTAL
Intervention: Botulinum toxin A (BT‐A)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo (isotonic saline)
Number of subjects: 23
Study: 16846450

Group type: EXPERIMENTAL
Intervention: Mite allergen impermeable mattress covers
Number of subjects: 1282

Group type: COMPARATOR
Intervention: Placebo covers
Number of subjects: 1282

Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 1282
Study: 12970916

Group type: EXPERIMENTAL
Intervention: Parenteral nutrition (PN) and enteral nutrition (EN) therapies
Number of subjects: 96

Group type: COMPARATOR
Intervention: Total parenteral nutrition (TPN) via central venous infusion
Number of subjects: 96
Study: 11169275

Group type: EXPERIMENTAL
Intervention: Chloroquine (CQ)
Number of subjects: 109
Study: 8599322

Group type: EXPERIMENTAL
Intervention: 56.3 mmol acetate/L
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 18.7 mmol propionate/L
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Acetate and propionate together
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 18.7 mmol acetate/L
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 56.3 mmol propionate/L
Number of subjects: 6
Study: 1457388

Group type: EXPERIMENTAL
Intervention: 10 mg/ml fluphenazine decanoate formulation
Number of subjects: 16

Group type: COMPARATOR
Intervention: 25 mg/ml standard fluphenazine decanoate formulation
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Pre-injection serum fluphenazine levels in a subgroup of 10 patients
Number of subjects: 16
Study: 6374050

Group type: EXPERIMENTAL
Intervention: Doxorubicin-based chemotherapy regimens (cyclophosphamide and doxorubicin alone or in combination with methotrexate or cisplatin)
Number of subjects: 537

Group type: EXPERIMENTAL
Intervention: Doxorubicin-based chemotherapy regimens
Number of subjects: 537

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 537
Study: 31192908

Group type: EXPERIMENTAL
Intervention: Sustained-release oxycodone (tablets, 12 hourly)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Immediate-release morphine (5 mg initially, hourly)
Number of subjects: 180
Study: 28364408

Group type: EXPERIMENTAL
Intervention: Locally prepared Bermuda grass pollen allergen extract
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Locally prepared Johnson grass pollen allergen extract
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Locally prepared careless weed pollen allergen extract
Number of subjects: 68

Group type: COMPARATOR
Intervention: Imported Bermuda grass pollen allergen extract
Number of subjects: 68

Group type: COMPARATOR
Intervention: Imported Johnson grass pollen allergen extract
Number of subjects: 68

Group type: COMPARATOR
Intervention: Imported careless weed pollen allergen extract
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Local and imported extracts
Number of subjects: 68

Group type: COMPARATOR
Intervention: Imported pollen extracts
Number of subjects: 68
Study: 27060050

Group type: EXPERIMENTAL
Intervention: Vitamin D3 2,000 IU/d
Number of subjects: 218

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 218
Study: 24182734

Group type: EXPERIMENTAL
Intervention: Expiratory muscle training (EMT) at 25% of maximum expiratory pressure
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Expiratory muscle training (EMT) at 75% of maximum expiratory pressure
Number of subjects: 34

Group type: COMPARATOR
Intervention: Saliva swallowing
Number of subjects: 34

Group type: COMPARATOR
Intervention: Water swallowing
Number of subjects: 34
Study: 22674921

Group type: EXPERIMENTAL
Intervention: Facilitated physical activity intervention (up to three face to face sessions and 10 telephone calls over eight months)
Number of subjects: 361

Group type: EXPERIMENTAL
Intervention: Facilitated physical activity intervention
Number of subjects: 361

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 361
Study: 19217260

Group type: EXPERIMENTAL
Intervention: Medium-chain triacylglycerols (MCTs)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 1,3-diacylglycerol (DG) oil
Number of subjects: 36

Group type: COMPARATOR
Intervention: Long-chain triacylglycerols (LCTs)
Number of subjects: 36
Study: 17889760

Group type: EXPERIMENTAL
Intervention: Henderson capsule tension ring (HCTR, Morcher)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Original 14C Morcher capsular tension ring
Number of subjects: 0
Study: 21213510

Group type: EXPERIMENTAL
Intervention: Single embryo transfer (fresh)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Double embryo transfer (fresh)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Single embryo transfer (cumulative)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Double embryo transfer (cumulative)
Number of subjects: 0
Study: 11441370

Group type: EXPERIMENTAL
Intervention: Fluoxetine (40 mg) in the acute study
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Fluoxetine (40 mg/d) in the chronic study
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo in the acute study
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo in the chronic study
Number of subjects: 23
Study: 9530056

Group type: EXPERIMENTAL
Intervention: Echo-enhanced Doppler sonography
Number of subjects: 30

Group type: COMPARATOR
Intervention: Unenhanced Doppler sonography
Number of subjects: 30
Study: 7978098

Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 2647040

Group type: EXPERIMENTAL
Intervention: Surfactant replacement
Number of subjects: 20
Study: 4570092

Group type: EXPERIMENTAL
Intervention: Neomycin sulfate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Phythalylsulfathiazole
Number of subjects: 0

Group type: COMPARATOR
Intervention: Iodochlorhydroxyquin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Furazolidone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Antimicrobial treatment and anti-diarrheal agents
Number of subjects: 0
Study: 30704329

Group type: EXPERIMENTAL
Intervention: Buddy taping
Number of subjects: 99

Group type: COMPARATOR
Intervention: Splint immobilization
Number of subjects: 99
Study: 28978289

Group type: EXPERIMENTAL
Intervention: Invitation to attend the clinic as a couple
Number of subjects: 37

Group type: COMPARATOR
Intervention: Invitation to attend the clinic as a couple plus clinic-led phone and community tracing
Number of subjects: 37
Study: 25693012

Group type: EXPERIMENTAL
Intervention: Pertuzumab, trastuzumab, and docetaxel
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo, trastuzumab, and docetaxel
Number of subjects: 0
Study: 22971724

Group type: EXPERIMENTAL
Intervention: Sprint exercise
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Endurance exercise
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Resistance exercise
Number of subjects: 8

Group type: COMPARATOR
Intervention: Seated rest
Number of subjects: 8
Study: 21868779

Group type: EXPERIMENTAL
Intervention: Exenatide (EXE)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Insulin glargine (GLAR)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Exenatide (EXE) and Insulin glargine (GLAR)
Number of subjects: 69
Study: 19506526

Group type: EXPERIMENTAL
Intervention: Ramipril
Number of subjects: 25588

Group type: EXPERIMENTAL
Intervention: Telmisartan
Number of subjects: 25588

Group type: EXPERIMENTAL
Intervention: Both Ramipril and Telmisartan
Number of subjects: 25588

Group type: COMPARATOR
Intervention: Control (no specific intervention mentioned)
Number of subjects: 25588
Study: 16613177

Group type: EXPERIMENTAL
Intervention: Reperfusion therapy, thrombolysis, or percutaneous coronary intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Medical treatment with various pharmacological agents
Number of subjects: 0
Study: 12845256

Group type: EXPERIMENTAL
Intervention: Visual laser ablation combined with transurethral resection of the prostate (VLAP+TURP)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Transurethral resection of the prostate (TURP) alone
Number of subjects: 105
Study: 10989852

Group type: EXPERIMENTAL
Intervention: Fibreoptic intubation through the intubating laryngeal mask (Group L)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Fibreoptic intubation using only a fibrescope (Group C)
Number of subjects: 124
Study: 9377881

Group type: EXPERIMENTAL
Intervention: VI strategy (increased flow back to initial set flow and then further increased by 25%)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: P strategy (pressure-limited breath feature coupled to a volume assist breath with pressure limit set at 75% and 100% of static elastic recoil pressure)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control (baseline flow dyssynchrony produced by reducing set flow by 50%)
Number of subjects: 16
Study: 8230517

Group type: EXPERIMENTAL
Intervention: Estramustine (560 to 700 mg orally per day)
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Mitomycin C (15 mg/m2 by intravenous infusion every 6 weeks)
Number of subjects: 171
Study: 3541419

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate slow release 120 mg once a day
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 30664829

Group type: EXPERIMENTAL
Intervention: Child self-reported depressive symptoms
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Parent-report of child depressive symptoms
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Interaction between child self-report and parent-report on child
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Children with high self-reported symptoms and parents reporting low depressive symptoms
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Children with low self-reported symptoms
Number of subjects: 181
Study: 26688178

Group type: EXPERIMENTAL
Intervention: Integrative education
Number of subjects: 240

Group type: COMPARATOR
Intervention: Usual education
Number of subjects: 240
Study: 27338452

Group type: EXPERIMENTAL
Intervention: Non-Alcoholic Beer (NAB)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Alcoholic Beer (AB)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Water (W)
Number of subjects: 7
Study: 24983446

Group type: EXPERIMENTAL
Intervention: Subcutaneous methotrexate (MTX) administration via prefilled autoinjector pen
Number of subjects: 62

Group type: COMPARATOR
Intervention: Oral methotrexate (MTX) administration
Number of subjects: 62
Study: 22248564

Group type: EXPERIMENTAL
Intervention: web-ICAIP (Individual Coping and Alcohol Intervention Program)
Number of subjects: 183

Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: web-ICAIP
Number of subjects: 183
Study: 19071884

Group type: EXPERIMENTAL
Intervention: Lanreotide Autogel 60 mg
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Lanreotide Autogel 90 mg
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Lanreotide Autogel 120 mg
Number of subjects: 50

Group type: COMPARATOR
Intervention: Lanreotide IRF 7 microg/kg
Number of subjects: 50
Study: 17598899

Group type: EXPERIMENTAL
Intervention: Lengthened multidisciplinary primary care team consultation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual general practitioner care
Number of subjects: 0
Study: 12969172

Group type: EXPERIMENTAL
Intervention: Postdilution hemodiafiltration (session B)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Mixed hemodiafiltration (session D)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Dialysis (session A)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Mixed hemodiafiltration (sessions C, D, and E)
Number of subjects: 20
Study: 10769580

Group type: COMPARATOR
Intervention: Alpha-tocopherol (vitamin E) supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Beta-carotene (vitamin A) supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Combined supplements of several antioxidant vitamins
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vitamin C supplementation
Number of subjects: 0
Study: 9333111

Group type: EXPERIMENTAL
Intervention: Erythromycin 1.5 gm/day for 4 days
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Itraconazole 200 mg/day for 4 days
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 8403714

Group type: EXPERIMENTAL
Intervention: Standard feeding (commercial milkshake taken immediately after injection)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Posture (standing versus sitting for 10 minutes postinjection)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Feeding of lipid after injection
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Further study of the acute effects of a milkshake in eight patients
Number of subjects: 32
Study: 3780286

Group type: EXPERIMENTAL
Intervention: 40 mg propranolol plus 12.5 mg hydrochlorothiazide twice daily
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 400 mg acebutolol plus 25 mg hydrochlorothiazide once daily
Number of subjects: 20
Study: 30896414

Group type: EXPERIMENTAL
Intervention: Partially hydrolysed cow's milk formula (pHF)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Extensively hydrolysed cow's milk formula (eHF)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Regular cow's milk formula (rCMF)
Number of subjects: 25
Study: 30369162

Group type: EXPERIMENTAL
Intervention: Corticosteroid injection
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: NSAID injection
Number of subjects: 52
Study: 27536081

Group type: EXPERIMENTAL
Intervention: Adapted physical activity (APA) program, conducted for 8 weeks, 2 sessions/week
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (CG) did not perform any physical activity
Number of subjects: 30
Study: 24603353

Group type: EXPERIMENTAL
Intervention: AM-101 0.81 mg/ml
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: AM-101 0.27 mg/ml
Number of subjects: 248

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 248
Study: 22399081

Group type: EXPERIMENTAL
Intervention: Hyaluronic acid
Number of subjects: 101

Group type: COMPARATOR
Intervention: Neutral vehicle (control)
Number of subjects: 101
Study: 20466440

Group type: EXPERIMENTAL
Intervention: PI-2301 (3 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PI-2301 (10 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PI-2301 (1 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 17678567

Group type: EXPERIMENTAL
Intervention: Fish oil/evening primrose oil (FSO/EPO) blend (456 mg DHA/d and 353 mg GLA/d)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (mixture of habitual dietary fatty acids)
Number of subjects: 20
Study: 15972565

Group type: EXPERIMENTAL
Intervention: Immediate antibiotics
Number of subjects: 807

Group type: EXPERIMENTAL
Intervention: Delayed antibiotics
Number of subjects: 807

Group type: COMPARATOR
Intervention: No offer of antibiotics
Number of subjects: 807

Group type: EXPERIMENTAL
Intervention: Information leaflet
Number of subjects: 807
Study: 12588776

Group type: EXPERIMENTAL
Intervention: Fenofibrate
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 11234243

Group type: EXPERIMENTAL
Intervention: Psychobiological nutritional rehabilitation (PNR)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Traditional nutritional rehabilitation (TNR)
Number of subjects: 40
Study: 8901654

Group type: EXPERIMENTAL
Intervention: Endothelin-1 (ET-1) infused intravenously at rates of 0.2, 1, and 8 pmol/kg per minute for 10-20 minutes.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Big endothelin-1 infused intravenously at rates of 0.2, 1, and 8 pmol/kg per minute for 20 minutes.
Number of subjects: 0
Study: 1856148

Group type: EXPERIMENTAL
Intervention: Once-daily dosing regimen
Number of subjects: 100

Group type: COMPARATOR
Intervention: Twice-daily dosing regimen
Number of subjects: 100
Study: 6136101

Group type: EXPERIMENTAL
Intervention: Lodoxamide tromethamine 0.01 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Lodoxamide tromethamine 0.1 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 31176362

Group type: EXPERIMENTAL
Intervention: Semi-automated validation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Manual validation
Number of subjects: 0
Study: 28711556

Group type: EXPERIMENTAL
Intervention: Belimumab
Number of subjects: 1175

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 1175
Study: 27633147

Group type: EXPERIMENTAL
Intervention: Closed-loop gastric electrical stimulation (CLGES)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Laparoscopic adjustable gastric band (LAGB)
Number of subjects: 160
Study: 24768290

Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine (100 mg)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Intravenous ketorolac (30 mg)
Number of subjects: 41
Study: 23021528

Group type: EXPERIMENTAL
Intervention: Topical lidocaine hydrochloride with 1:100,000 epinephrine
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine hydrochloride with 1:200,000 epinephrine
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 0.5% ropivacaine
Number of subjects: 120

Group type: COMPARATOR
Intervention: 0.9% saline
Number of subjects: 120
Study: 19898218

Group type: EXPERIMENTAL
Intervention: PegIntron 0.5 microg/kg
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: PegIntron 1.0 microg/kg
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: PegIntron 1.5 microg/kg
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: PegIntron 3.0 microg/kg
Number of subjects: 259

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: PegIntron (all doses)
Number of subjects: 259
Study: 17325604

Group type: EXPERIMENTAL
Intervention: 0.5 mg Gag/Pol DNA vaccine
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 1.5 mg Gag/Pol DNA vaccine
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 4 mg Gag/Pol DNA vaccine
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Gag/Pol DNA vaccine (all doses)
Number of subjects: 21
Study: 12973849

Group type: EXPERIMENTAL
Intervention: 8-drugs-in-1-day regimen
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control regimen (lomustine, vincristine, and prednisone)
Number of subjects: 70
Study: 10374248

Group type: EXPERIMENTAL
Intervention: Banxia Houpo Tang (BHT) 7.5 g per day for four weeks
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Banxia Houpo Tang (BHT)
Number of subjects: 32
Study: 8678102

Group type: EXPERIMENTAL
Intervention: Cefepime (2 g thrice daily)
Number of subjects: 216

Group type: COMPARATOR
Intervention: Comparator regimens (ceftazidime 2 g thrice daily or piperacillin + gentamicin 3 g every 4 hours + 1.5 mg/kg every 8 hours)
Number of subjects: 216
Study: 1798839

Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Scopolamine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study: 7082781

Group type: EXPERIMENTAL
Intervention: Tablet dosage forms (three different tablet products)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Reference solution
Number of subjects: 12
Study: 30673051

Group type: EXPERIMENTAL
Intervention: Auricular acupuncture
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Treatment group
Number of subjects: 110

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 110
Study: 29226727

Group type: EXPERIMENTAL
Intervention: RA patients
Number of subjects: 85

Group type: COMPARATOR
Intervention: IL1RN*2/2 homozygous genotype in CS
Number of subjects: 85

Group type: COMPARATOR
Intervention: IL1RN*2/2 genotype in CS
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: RA patients with IL1RN*long/long genotype
Number of subjects: 85

Group type: COMPARATOR
Intervention: Carriers of IL1RN*2/2 genotype
Number of subjects: 85
Study: 26343591

Group type: EXPERIMENTAL
Intervention: Active anodal tDCS (1.5 mA)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 45